BRTX stock is moving higher after cover story in IEEE Pulse.

BioRestorative Therapies (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today feature coverage in the news outlet, IEEE Pulse, a magazine of the IEEE Engineering in Medicine and Biology Society. According to IEEE, it is “the world’s largest technical professional organization for the advancement of technology.” To view the IEEE Pulse Magazine’s article featuring BioRestorative go to https://pulse.embs.org/november-2019/stem-cell-therapies-low-back-pain/

The published cover-story article features commentary from Francisco Silva, Chief Scientist and Vice President of Research and Development for BioRestorative, regarding BRTX-100, the Company’s lead therapeutic candidate for chronic lumbar disc disease. “Once the U.S. Food and Drug Administration (FDA) authorizes the sale of BRTX-100, we would ship it to your doctor, and with a 30-minute procedure the material would be injected into your disc in a 1.5 ml solution,” explains Silva. He elaborates on the product, discussing growing and expanding stem cells from the patient’s bone marrow under hypoxic conditions that mimic those in the normal intervertebral space. “We are enriching the cells to be able to survive in this harsh environment,” says Silva.

In addition to BRTX-100, the magazine article also highlights BioRestorative’s other research pursuit, its ThermoStem® program, utilizing brown adipose (fat) derived stem cells to target treatment of metabolic diseases and disorders, like diabetes, obesity and hypertension.

BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.

BioRestorative Therapies News From Google